Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma [Phase 2]
This entry describes a Phase 2 clinical trial of low-dose mosunetuzumab for indolent B-cell lymphomas, currently recruiting at the Universit…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating Rituximab plus Venetoclax as frontline therapy for marginal zone lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Lisaftoclax (APG-2575) as a monotherapy in indolent lymphomas, including Waldenström mac…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies [Phase 1]
Phase 1 clinical trial update of BGB-21447, a Bcl-2 inhibitor developed by BeOne Medicines, evaluating safety and preliminary activity in mu…
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas [Phase 1, Phase 2]
Phase 1/2 study evaluating the combination of lenalidomide with DA-EPOCH-R in MYC-associated B-cell lymphomas has completed, and results hav…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating ixazomib citrate with rituximab in indolent B-cell non-Hodgkin lymphoma has posted results.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL [Phase 2]
This record describes an ongoing Phase 2 clinical trial evaluating orelabrutinib in combination with rituximab, with or without lenalidomide…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers [Phase 1]
Phase 1 study of oral LOXO-338 in advanced blood cancers is ongoing, with status listed as active but not recruiting.
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL [Phase 2]
An exploratory Phase 2 clinical trial evaluating Orelabrutinib for early-stage, untreated marginal zone lymphoma is currently recruiting in …
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma [Phase 2]
A Phase 2 trial evaluating initial therapy with Umbralisib plus Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma was terminated,…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY [Phase 2]
Phase II multicenter open-label single-arm study of pembrolizumab in marginal zone lymphoma was terminated; results have been posted.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma [Phase 2]
Phase 2 trial evaluating Orelabrutinib followed by response-adapted ultra-low-dose 4 Gy radiation as first-line therapy for mucosa-associate…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) [Phase 2]
A Phase 2 clinical trial evaluating orelabrutinib in combination with BR/G as first-line therapy for untreated marginal zone lymphoma is cur…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
A Mayo Clinic-sponsored clinical trial (HALT) is evaluating strategies to manage hypertension and prevent cardiovascular adverse events in p…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CAR-20/19-T cells in relapsed or refractory B-cell malignancies, including multiple non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies [Phase 1]
A Phase 1 clinical trial is investigating LV20.19 CAR T-cells in combination with pirtobrutinib for relapsed or refractory B-cell malignanci…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab [Phase 1, Phase 2]
BeiGene announced completion and posted results for a Phase 1/2 study of BGB-10188 as monotherapy and in combination with zanubrutinib and t…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study of APG-3288 in Relapsed/Refractory Blood Cancers [Phase 1]
Phase 1 study of APG-3288 in relapsed/refractory hematologic cancers; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas [Phase 2]
Phase 2 trial evaluating frontline obinutuzumab and ibrutinib in indolent non-Hodgkin lymphoma is active but not recruiting, per ClinicalTri…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Epco, Zanu, Ritux for R/R FL or MZL [Phase 2]
Phase 2 clinical trial recruiting to evaluate Epco, Zanu, and rituximab in relapsed/refractory follicular lymphoma and marginal zone lymphom…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas [Phase 3]
This clinical trial update describes a Phase 3 study evaluating reduced-dose radiation therapy for people with B-cell lymphomas, specificall…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]
A Phase 1 clinical trial evaluating oral LP-168 in relapsed or refractory B-cell malignancies is recruiting. Target conditions include CLL/S…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of SGR-1505 in Mature B-Cell Neoplasms [Phase 1]
Schrödinger's SGR-1505 is being evaluated in a Phase 1 trial across multiple mature B-cell neoplasms and is currently recruiting. The study …
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies [Phase 1]
Phase 1 clinical trial from Mayo Clinic is evaluating BAFFR-based CAR-T cells with lymphodepletion (fludarabine and cyclophosphamide) for re…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial assessing the safety of LTZ-301 in patients with various forms of non-Hodgkin lymphoma, currently recruiting.